Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Generation of antibody-based therapeutics targeting the Idiotype of B-cell Malignancies.

Weiss E, Sarnovsky R, Ho M, Arons E, Kreitman R, Angelus E, Antignani A, FitzGerald D.

Antib Ther. 2019 Jan;2(1):1-10. doi: 10.1093/abt/tby012. Epub 2018 Dec 27.

2.

Tofacitinib enhances delivery of antibody-based therapeutics to tumor cells through modulation of inflammatory cells.

Simon N, Antignani A, Hewitt SM, Gadina M, Alewine C, FitzGerald D.

JCI Insight. 2019 Mar 7;4(5). pii: 123281. doi: 10.1172/jci.insight.123281. eCollection 2019 Mar 7.

3.

Essential role for Bim in mediating the apoptotic and antitumor activities of immunotoxins.

Antignani A, Segal D, Simon N, Kreitman RJ, Huang D, FitzGerald DJ.

Oncogene. 2017 Aug 31;36(35):4953-4962. doi: 10.1038/onc.2017.111. Epub 2017 Apr 24.

PMID:
28436946
4.

Chemical Screens Identify Drugs that Enhance or Mitigate Cellular Responses to Antibody-Toxin Fusion Proteins.

Antignani A, Mathews Griner L, Guha R, Simon N, Pasetto M, Keller J, Huang M, Angelus E, Pastan I, Ferrer M, FitzGerald DJ, Thomas CJ.

PLoS One. 2016 Aug 24;11(8):e0161415. doi: 10.1371/journal.pone.0161415. eCollection 2016.

5.

Ranking Differential Drug Activities from Dose-Response Synthetic Lethality Screens.

Guha R, Mathews Griner LA, Keller JM, Zhang X, Fitzgerald D, Antignani A, Pastan I, Thomas CJ, Ferrer M.

J Biomol Screen. 2016 Oct;21(9):942-55. doi: 10.1177/1087057116644890. Epub 2016 Apr 25.

PMID:
27112173
6.

Targeting a Cancer-Specific Epitope of the Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer.

Simon N, Antignani A, Sarnovsky R, Hewitt SM, FitzGerald D.

J Natl Cancer Inst. 2016 Apr 13;108(8). doi: 10.1093/jnci/djw028. Print 2016 Aug.

7.

Characterization of the membrane-inserted C-terminus of cytoprotective BCL-XL.

Yao Y, Nisan D, Fujimoto LM, Antignani A, Barnes A, Tjandra N, Youle RJ, Marassi FM.

Protein Expr Purif. 2016 Jun;122:56-63. doi: 10.1016/j.pep.2016.02.010. Epub 2016 Feb 23.

8.

Conformation of BCL-XL upon Membrane Integration.

Yao Y, Fujimoto LM, Hirshman N, Bobkov AA, Antignani A, Youle RJ, Marassi FM.

J Mol Biol. 2015 Jul 3;427(13):2262-70. doi: 10.1016/j.jmb.2015.02.019. Epub 2015 Feb 27.

9.

Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicity.

Pasetto M, Antignani A, Ormanoglu P, Buehler E, Guha R, Pastan I, Martin SE, FitzGerald DJ.

Proc Natl Acad Sci U S A. 2015 Mar 10;112(10):E1135-42. doi: 10.1073/pnas.1501958112. Epub 2015 Feb 23.

10.

ABT-737 promotes the dislocation of ER luminal proteins to the cytosol, including pseudomonas exotoxin.

Antignani A, Sarnovsky R, FitzGerald DJ.

Mol Cancer Ther. 2014 Jun;13(6):1655-63. doi: 10.1158/1535-7163.MCT-13-0998. Epub 2014 Apr 16.

11.

Combining the antimesothelin immunotoxin SS1P with the BH3-mimetic ABT-737 induces cell death in SS1P-resistant pancreatic cancer cells.

Hollevoet K, Antignani A, Fitzgerald DJ, Pastan I.

J Immunother. 2014 Jan;37(1):8-15. doi: 10.1097/CJI.0000000000000010.

PMID:
24316551
12.

Immunotoxins: the role of the toxin.

Antignani A, Fitzgerald D.

Toxins (Basel). 2013 Aug 21;5(8):1486-502. doi: 10.3390/toxins5081486. Review.

13.

Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737.

Fitzgerald DJ, Moskatel E, Ben-Josef G, Traini R, Tendler T, Sharma A, Antignani A, Mussai F, Wayne A, Kreitman RJ, Pastan I.

Leuk Lymphoma. 2011 Jun;52 Suppl 2:79-81. doi: 10.3109/10428194.2011.569961. Review.

PMID:
21599608
14.

ABT-737 overcomes resistance to immunotoxin-mediated apoptosis and enhances the delivery of pseudomonas exotoxin-based proteins to the cell cytosol.

Traini R, Ben-Josef G, Pastrana DV, Moskatel E, Sharma AK, Antignani A, Fitzgerald DJ.

Mol Cancer Ther. 2010 Jul;9(7):2007-15. doi: 10.1158/1535-7163.MCT-10-0257. Epub 2010 Jun 29.

15.

Initial characterization of an immunotoxin constructed from domains II and III of cholera exotoxin.

Sarnovsky R, Tendler T, Makowski M, Kiley M, Antignani A, Traini R, Zhang J, Hassan R, FitzGerald DJ.

Cancer Immunol Immunother. 2010 May;59(5):737-46. doi: 10.1007/s00262-009-0794-4. Epub 2009 Nov 29.

PMID:
20091030
16.

Bax activates endophilin B1 oligomerization and lipid membrane vesiculation.

Rostovtseva TK, Boukari H, Antignani A, Shiu B, Banerjee S, Neutzner A, Youle RJ.

J Biol Chem. 2009 Dec 4;284(49):34390-9. doi: 10.1074/jbc.M109.021873. Epub 2009 Oct 5.

17.

Proteolytic cleavage of a C-terminal prosequence, leading to autoprocessing at the N Terminus, activates leucine aminopeptidase from Pseudomonas aeruginosa.

Sarnovsky R, Rea J, Makowski M, Hertle R, Kelly C, Antignani A, Pastrana DV, Fitzgerald DJ.

J Biol Chem. 2009 Apr 10;284(15):10243-53. doi: 10.1074/jbc.M808686200. Epub 2009 Feb 11.

18.

p47phox-deficient immune microenvironment signals dysregulate naive T-cell apoptosis.

Donaldson M, Antignani A, Milner J, Zhu N, Wood A, Cardwell-Miller L, Changpriroa CM, Jackson SH.

Cell Death Differ. 2009 Jan;16(1):125-38. doi: 10.1038/cdd.2008.129. Epub 2008 Sep 19.

19.

Endosome fusion induced by diphtheria toxin translocation domain.

Antignani A, Youle RJ.

Proc Natl Acad Sci U S A. 2008 Jun 10;105(23):8020-5. doi: 10.1073/pnas.0711707105. Epub 2008 Jun 6.

21.

How do Bax and Bak lead to permeabilization of the outer mitochondrial membrane?

Antignani A, Youle RJ.

Curr Opin Cell Biol. 2006 Dec;18(6):685-9. Epub 2006 Oct 12. Review.

PMID:
17046225
22.
23.

Engineering the refolding pathway and the quaternary structure of seminal ribonuclease by newly introduced disulfide bridges.

Russo A, Antignani A, Giancola C, D'Alessio G.

J Biol Chem. 2002 Dec 13;277(50):48643-9. Epub 2002 Oct 10.

24.

The Antarctic Psychrobacter sp. TAD1 has two cold-active glutamate dehydrogenases with different cofactor specificities. Characterisation of the NAD+-dependent enzyme.

Camardella L, Di Fraia R, Antignani A, Ciardiello MA, di Prisco G, Coleman JK, Buchon L, Guespin J, Russell NJ.

Comp Biochem Physiol A Mol Integr Physiol. 2002 Mar;131(3):559-67.

PMID:
11867281
25.

Antitumor action of seminal ribonuclease, its dimeric structure, and its resistance to the cytosolic ribonuclease inhibitor.

Antignani A, Naddeo M, Cubellis MV, Russo A, D'Alessio G.

Biochemistry. 2001 Mar 27;40(12):3492-6.

PMID:
11297415
26.

In vitro evolution of a dimeric variant of human pancreatic ribonuclease.

Russo N, Antignani A, D'Alessio G.

Biochemistry. 2000 Apr 4;39(13):3585-91.

PMID:
10736157
27.

NADP+-dependent glutamate dehydrogenase in the Antarctic psychrotolerant bacterium Psychrobacter sp. TAD1. Characterization, protein and DNA sequence, and relationship to other glutamate dehydrogenases.

Di Fraia R, Wilquet V, Ciardiello MA, Carratore V, Antignani A, Camardella L, Glansdorff N, Di Prisco G.

Eur J Biochem. 2000 Jan;267(1):121-31.

28.

Predictors of mortality in hemodialysis patients.

Goldwasser P, Mittman N, Antignani A, Burrell D, Michel MA, Collier J, Avram MM.

J Am Soc Nephrol. 1993 Mar;3(9):1613-22.

29.

The uremic dyslipidemia: a cross-sectional and longitudinal study.

Avram MM, Goldwasser P, Burrell DE, Antignani A, Fein PA, Mittman N.

Am J Kidney Dis. 1992 Oct;20(4):324-35.

PMID:
1415199
30.

Lipid abnormalities in black renal patients.

Burrell DE, Antignani A, Goldwasser P, Mittman N, Fein PA, Slater PA, Gan A, Avram MM.

N Y State J Med. 1991 May;91(5):192-6.

PMID:
1857570
31.

Effect of urine chemistry on red cells.

Goldwasser P, Antignani A, Avram MM.

Nephron. 1991;59(2):328-9. No abstract available.

32.
33.

Longitudinal survey of apolipoproteins and atherogenic risk in hemodialysis and continuous ambulatory peritoneal dialysis patients.

Burrell D, Antignani A, Fein PA, Goldwasser P, Mittman N, Avram MM.

ASAIO Trans. 1990 Jul-Sep;36(3):M331-5.

PMID:
2123635
34.

Urinary red cell size: diagnostic value and determinants.

Goldwasser P, Antignani A, Mittman N, Rao Y, Mushnick RA, Norbergs A, DiPillo F, Avram MM.

Am J Nephrol. 1990;10(2):148-56.

PMID:
2349958
35.

The impact of CAPD treatment on lipid metabolism and cardiovascular risk.

Tan D, Fein PA, Antignani A, Mittman N, Avram MM.

Adv Perit Dial. 1990;6:233-7.

PMID:
1982815
36.

Cholesterol and lipid disturbances in renal disease: the natural history of uremic dyslipidemia and the impact of hemodialysis and continuous ambulatory peritoneal dialysis.

Avram MM, Fein PA, Antignani A, Mittman N, Mushnick RA, Lustig AR, Lapuz MH, Goldwasser P.

Am J Med. 1989 Nov;87(5N):55N-60N.

PMID:
2486549
37.

Fall of cholesterol with time on dialysis: impact on atherogenicity.

Lapuz M, Avram MM, Lustig A, Goldwasser P, Antignani A, Fein PA, Mittman N.

ASAIO Trans. 1989 Jul-Sep;35(3):258-60.

PMID:
2597459
38.

Variability of peritoneal clearances for apolipoprotein and its relationship to susceptibility for atherosclerotic changes in CAPD.

Fein PA, Fletcher D, Antignani A, Goldwasser P, Jorden A, Lustig A, Avram MM.

Adv Perit Dial. 1989;5:185-90.

PMID:
2577408
39.

Lipids in diabetic and nondiabetic hemodialysis and CAPD patients.

Avram MM, Antignani A, Goldwasser P, Lustig A, Fein PA, Mushnick R, Quinones E, Rao Y, Mittman N.

ASAIO Trans. 1988 Jul-Sep;34(3):314-6.

PMID:
3196527
40.

Specificity and biological activity of the protein deposited on the hydrogel surface. Relationship of polymer structure to biofilm formation.

Sack RA, Jones B, Antignani A, Libow R, Harvey H.

Invest Ophthalmol Vis Sci. 1987 May;28(5):842-9.

PMID:
3570694

Supplemental Content

Loading ...
Support Center